Insomnia is reported by approximately 30% of the U.S. population, with 5% to 15% diagnosed with chronic insomnia, which can significantly impair quality of life, productivity, and overall health. The American Academy of Sleep Medicine defines insomnia as difficulty with sleep initiation, duration, consolidation, or quality, leading to daytime impairment. Chronic insomnia is characterized by symptoms occurring at least three times per week over three months.
Read More
Initial management focuses on nonpharmacologic therapies, particularly cognitive behavior therapy for insomnia (CBT-I). This approach addresses negative thought patterns through methods such as sleep restriction, stimulus control, and relaxation techniques. Other nonpharmacologic treatments can include exercise, mindfulness practices, and acupuncture. If these strategies prove ineffective, pharmacologic treatments may be considered.
Benzodiazepines and Z-drugs, while commonly prescribed, carry significant risks and should be avoided if possible. Melatonin receptor agonists are generally safer but may have limited effectiveness. Dual orexin receptor antagonists have shown efficacy for patients experiencing difficulties with sleep maintenance or onset. The effectiveness of antihistamines for insomnia lacks strong evidence, though doxylamine has shown efficacy for short-term use.
The primary recommendation is to prioritize CBT-I as the first-line intervention for chronic insomnia, as evidenced by systematic reviews indicating improvements in various sleep-related metrics. It is advised not to prescribe hypnotics as the sole initial treatment and to avoid long-term use of benzodiazepines and other sedative-hypnotics for older adults.
A thorough evaluation of insomnia should involve a comprehensive medical and psychiatric history, assessments of sleep-related behaviors, and preparation for potential underlying conditions influencing insomnia. Healthy sleep hygiene practices like maintaining a regular sleep schedule, minimizing screen time before bed, and optimizing sleep environments are vital.
CBT-I comprises five essential components: cognitive restructuring, stimulus control, sleep hygiene, relaxation therapy, and sleep restriction. Combining these components has yielded better outcomes than using them individually. While other nonpharmacologic therapies, including brief interventions and mindfulness practices, have shown benefit, they are most effective when paired with CBT-I.
When pharmacologic treatment is necessary, several classes of medications, including sedative-hypnotics, melatonin receptor agonists, and dual orexin receptor antagonists may be considered. Patients should be closely monitored to mitigate risks associated with these medications, particularly those classified as schedule IV drugs by the U.S. Drug Enforcement Administration.
Lastly, ongoing research and updates in pharmacology and treatment protocols continue to shape the management of chronic insomnia, ensuring that healthcare providers have access to the latest evidence-based practices.